Author:
Cressey Tim R,Turkova Anna
Reference7 articles.
1. Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries;Penazzato;J Int AIDS Soc,2018
2. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study;Rodriguez;Lancet HIV,2024
3. Custodio JM, West SK, Collins S, et al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. Conference on Retroviruses and Opportunistic Infections; March 4–7, 2018 (presentation 34).
4. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide;Cerrone;J Antimicrob Chemother,2019
5. INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial